Warehouse and shipping updatesCheck the selected warehouse and delivery eligibility before placing an order.
2026CATALOG
Maven

Browse

Maven research note · 2026-10-27

Peptide Therapeutics: From Sequence Design to Developability

A practical view of why peptides occupy a useful space between small molecules and larger biologics, and which design constraints shape viable research candidates.

Why peptides are a distinct modality

Peptides can present a larger and more structured interaction surface than many small molecules while remaining chemically defined and sequence-addressable. That combination supports research on targets that are difficult to approach with compact compounds, but it also introduces liabilities in stability, permeability and exposure.

Developability begins with sequence

Length, charge distribution, hydrophobicity, secondary-structure tendency and modification sites influence solubility, aggregation, chemical degradation and manufacturability. Candidate comparison is stronger when biological activity is considered alongside these physical and analytical properties from the beginning.

A staged evidence package

Identity, purity, potency, stability and delivery questions require different methods. A defensible program separates discovery evidence from release testing and records which conclusions come from sequence design, analytical characterization or functional assays.